NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease ID1514

Provisional Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Company/sponsor	General commentators
AstraZeneca (ticagrelor)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	 Allied Health Professionals Federation
BEMDA: Black and Ethnic Minority Diabetes Association	Board of Community Health Councils in Wales
Black Health Agency	British National Formulary
Blood Pressure UK	Care Quality Commission
British Cardiac Patients Association	Department of Health, Social Services
Cardiac Risk in the Young	and Public Safety for Northern Ireland
Cardiomyopathy UK	Diabetes UK Cymru
Cardiovascular Care Partnership	Healthcare Improvement Scotland
Coronary Prevention Group	Medicines and Healthcare Products
Diabetes Research and Wellness	Regulatory Agency
Foundation	 National Association of Primary Care
Diabetes UK	National Pharmacy Association
Different Strokes	NHS Alliance
HEART UK	NHS Confederation
InDependent Diabetes Trust	Scottish Medicines Consortium
Muslim Council of Britain	Welsh Health Specialised Services
Network of Sikh Organisations	Committee
Pumping Marvellous	Oommittee
	Comparators
Somerville FoundationSouth Asian Health Foundation	Accord Healthcare (aspirin, clopidogrel)
	Actavis UK (clopidogrel)
Specialised Healthcare Alliance Strake Information	Alliance Pharmaceuticals (aspirin)
Stroke Information The Stroke Association	Aurobindo Pharma – Milpharm
The Stroke Association Thrombosis LIV	(clopidogrel)
Thrombosis UK	Concordia International (aspirin)
Drefessional groups	Dexcel Pharam (aspirin)
Professional groups	Dr Reddy's Laboratories (aspirin)
Association of British Clinical Diabetalogists	Glaxosmithkline consumer healthcare
Diabetologists Pritish and Irish Hyportonsian Society	(aspirin)
British and Irish Hypertension Society British Association for Nursing in	 Intrapharm Laboratories (aspirin)
British Association for Nursing in Cardiovascular Care	Kent Pharmaceuticals (clopidogrel)
	Martindale Pharma (aspirin)
British Association of Stroke Physicians	Pfizer Consumer Healthcare (aspirin,
Physicians	atorvastatin)
British Atherosclerosis Society	atorvastatiri)

- British Cardiovascular Intervention Society
- British Cardiovascular Society
- British Geriatrics Society
- British Heart Foundation
- British Heart Rhythm Society
- British Institute of Radiology
- British Nuclear Cardiology Society
- British Society for Cardiovascular Research
- British Society for Haematology
- British Society for Haemostasis and Thrombosis
- British Society for Heart Failure
- British Society of Cardiovascular Imaging
- British Thoracic Society
- Clinical Leaders of Thrombosis
- Primary Care Diabetes Society
- Royal College of Emergency Medicine
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- Society for Cardiological Science and Technology
- Society for Endocrinology
- Society of Vascular Nurses
- Society of Vascular Technology
- TREND UK
- UK Clinical Pharmacy Association
- UK Health Forum
- Vascular Society of Great Britain and Ireland

Others

- Department of Health and Social Care
- NHS Chorley and South Ribble CCG
- NHS England
- NHS North Manchester CCG
- Welsh Government

- Reckitt Benckiser Healthcare UK (aspirin)
- Sandoz (clopidogrel)
- Sanofi (clopidogrel)
- Teva UK (aspirin)
- Thornton and Ross (aspirin)
- Zentiva (aspirin, clopidogrel)

Relevant research groups

- British Society for Cardiovascular Research
- Cardiac and Cardiology Research Dept, Barts
- Circulation Foundation
- Central Cardiac Audit Database
- Cochrane Heart Group
- Cochrane Hypertension Group
- Cochrane Metabolic & Endocrine Disorders Group
- Cochrane Stroke Group
- Cochrane Vascular
- European Council for Cardiovascular Research
- Genomics England
- Heart Research UK
- MRC Clinical Trials Unit
- National Centre for Cardiovascular Preventions and Outcomes
- National Institute for Health Research
- Wellcome Trust

Associated Public Health Groups

- Public Health England
- Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that manufactures the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that manufactures the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary.

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.